Gemin X Biotechnologies Inc. Initiates a Phase 1 Trial with GMX1777 in Solid Tumors and Lymphomas
MONTREAL & BALLERUP, Denmark--(BUSINESS WIRE)--Gemin X announced today that it has initiated a Phase 1 clinical trial with GMX1777 in patients with refractory solid tumors and lymphomas. The compound, licensed worldwide from LEO Pharma, is a water-soluble, intravenously administered prodrug of the LEO Pharma compound CHS828.